Bringing patient-specific tumor targeted immunotherapies to
the world, one patient
at a time.
Our Passion
At Geneos, our passion is to develop Exquisitely Personalized Immunotherapies to unleash the most powerful force against Cancer: your body’s own immune system.
We have established our GT-EPIC™ Platform to drive development of individualized treatments.
Our Approach
Our approach is to target unique neoantigens (abnormal mutations and genomic variations produced by cancer cells) from individual patient tumors to develop novel treatments for cancer. Our technology is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor- specific neoantigen-targeted personalized immunotherapies.
Highlights
01
Geneos addresses the heterogeneous nature of cancer by leveraging its powerful, proprietary, immunotherapy platform, GT-EPIC™, to develop tumor-specific neoantigen targeted personalized immunotherapies
02
03
The GT-EPIC™ platform drives T cells, and in particular, antigen specific CD8+ T cells with a killing function. Tumor targeted T cells are the key effectors of tumor cell death
04
Latest News
Upcoming Conferences
Please stay tuned for a list of upcoming conferences Geneos will be attending.
Geneos will be attending the following upcoming conferences:
JP Morgan Annual Healthcare Conference
January 2022
Previously attended conferences:
- Next Generation Cancer Vaccine Development Summit
Sep 7-9, 2021 - ESMO Congress 2021
Sep 17-21, 2021 - Biopharma Conclave
Sep 29-30, 2021 - Neoantigen Based Therapies Summit
Oct 26-28, 2021